ijms-logo

Journal Browser

Journal Browser

Editorial Board Members’ Collection Series: Autoimmune Diseases—2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 March 2025 | Viewed by 1218

Special Issue Editors


E-Mail Website
Guest Editor

E-Mail Website
Guest Editor
Institute of Biotechnology, Faculty Environment and Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, 01968 Senftenberg, Germany
Interests: molecular diagnostics; quality management; autoimmune diseases; personalized medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, dedicated to autoimmunity, attempts to present a comprehensive overview of autoimmune diseases (ADs) and how the immune system self-targets in different conditions according to a balance determined by the genetic predisposition of the host, its gender, epigenetic factors, environmental circumstances, and other co-factors. Moreover, current knowledge from human and animal models is welcome regarding the pathogenic mechanisms of autoimmune diseases, clinical aspects of specific autoimmune diseases, as well as insights regarding biomarkers and specific therapies.

Prof. Dr. Yves Renaudineau
Dr. Dirk Roggenbuck
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoimmunity
  • autoimmune diseases
  • immunotherapy
  • biomarkers
  • pathogenic mechanisms

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1582 KiB  
Article
Increased Cytokine Levels in Seronegative Myositis: Potential Th17 Immune Response Implications
by Andrea Aguilar-Vazquez, Efrain Chavarria-Avila, José Manuel Gutiérrez-Hernández, Guillermo Toriz-González, Mario Salazar-Paramo, Gabriel Medrano-Ramirez, Steven Vargas-Cañas, Oscar Pizano-Martinez, Cynthia-Alejandra Gomez-Rios, Christian Juarez-Gomez, José-David Medina-Preciado, Maribell Cabrera-López, Edgar-Federico Quirarte-Tovar, Ligia Magaña-García, Alejandra-Rubí García-Gallardo, Edy-David Rubio-Arellano and Monica Vazquez-Del Mercado
Int. J. Mol. Sci. 2024, 25(20), 11061; https://doi.org/10.3390/ijms252011061 - 15 Oct 2024
Viewed by 823
Abstract
Th17 cells are known for producing IL-17 and their role in the pathogenesis of various autoimmune diseases, including myositis. Likewise, the participation of the IL-23/IL-17 pathway in autoimmunity has been confirmed. In this study, we aimed to evaluate the behavior of cytokines in [...] Read more.
Th17 cells are known for producing IL-17 and their role in the pathogenesis of various autoimmune diseases, including myositis. Likewise, the participation of the IL-23/IL-17 pathway in autoimmunity has been confirmed. In this study, we aimed to evaluate the behavior of cytokines in myositis, focusing on the autoantibodies profile and the myositis core set measures. Twenty-five myositis patients were enrolled in this cross-sectional study. An expert rheumatologist evaluated the myositis core set measures. Serum levels of cytokines and chemokines were quantified using the LEGENDplex Multi-Analyte Flow Assay Kit from BioLegend. The autoantibodies detection was carried out using the line-blot assay kit Euroline: Autoimmune Inflammatory Myopathies from EUROIMMUN. We found higher serum levels of IL-33, CXCL8, IL-6, IL-23, and IL-12p70 in seronegative patients. A multiple linear regression analysis revealed that MYOACT scores could be predicted by the increment of IL-23 and the decrement of CCL2, IL-10, and CXCL8 serum levels. These findings suggest that the immune response in seronegative myositis patients exhibits an IL-23-driven Th17 immune response. The relevance of this discovery lies in its potential therapeutic implications. Insights into the IL-23-driven Th17 immune response in seronegative patients highlight the potential for targeted therapies aimed at modulating Th17 activity. Full article
Show Figures

Figure 1

Back to TopTop